Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials Jean L. GremD. Dale ShoemakerBrian Leyland-Jones Preclinical Review Pages: 315 - 328
Structure and activity relationship of several novel CC-1065 analogs Li H. LiTanya L. WallaceWilliam C. Krueger Preclinical Studies Pages: 329 - 337
A new antitumor antibiotic FR66973: clonogenic in vitro assessment of activity against human non-small cell lung carcinoma Fumihiko KanzawaYuka MatsushimaNagahiro Saijo Preclinical Studies Pages: 339 - 343
Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo Steadman D. Harrison Jr.R. Wallace BrockmanDaniel P. Griswold Jr. Preclinical Studies Pages: 345 - 351
In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay Yasutsuna SasakiFumihiko KanzawaNagahiro Saijo Preclinical Studies Pages: 353 - 359
Brain uptake and CNS levels of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (HECNU) C. UngerH. EiblG. Eisenbrand Preclinical Studies Pages: 361 - 364
Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion Richard PazdurGuy G. ChabotLaurence H. Baker Clinical Studies Pages: 365 - 371
Phase II evaluation of Aclacinomycin-A in advanced ovarian carcinoma Silvana MartinoDavid A. DeckerCynthia L. Kresge Clinical Studies Pages: 373 - 374
Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada clinical trials group study Elizabeth A. EisenhauerJean A. MarounPaul L. D. Walde Clinical Studies Pages: 375 - 378
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C) C. Philip SteuberVita J. LandTeresa J. Vietti Clinical Studies Pages: 379 - 382
Mitoxantrone in the treatment of acute leukemia Daniel A. VorobiofGeoffrey FalksonAletta P. S. Terblanche Clinical Studies Pages: 383 - 388
